PF-4136309 1 mg | 99.52%
TargetMol
PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.
More Information Supplier Page
PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.
More Information Supplier Page
B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor.
More Information Supplier Page
B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor.
More Information Supplier Page
MLN1117 (INK1117) is a p110α/β/γ/δ inhibitor (IC50: 15/4.5/1.9/13.39 μM).
More Information Supplier Page
UNC1999 is a orally bioavailable, effective and specific inhibitor of EZH2 (IC50=2 nM) and EZH1 (IC50=45).
More Information Supplier Page
PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.
More Information Supplier Page
PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.
More Information Supplier Page
ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM).
More Information Supplier Page
WAY-100635 is a specific and effective 5-HT receptor antagonist (IC50=0.95 nM).
More Information Supplier Page
WAY-100635 is a specific and effective 5-HT receptor antagonist (IC50=0.95 nM).
More Information Supplier Page